ICO Gauducheau

Saint-Herblain, France

ICO Gauducheau

Saint-Herblain, France
SEARCH FILTERS
Time filter
Source Type

Demoor-Goldschmidt C.,French Institute of Health and Medical Research | Supiot S.,ICO Gauducheau | Oberlin O.,Institute Gustave Roussy | Helfre S.,University Pierre and Marie Curie | And 8 more authors.
Radiotherapy and Oncology | Year: 2017

Purpose: Irradiation (>3. Gy) to the breast or axillae before 30. years of age increases the risk of secondary breast cancer (SBC). The purpose of this article is to describe the clinical characteristics of SBC and the way of diagnosis in young women (before the age of national screening) in France who had received previous radiotherapy for a childhood or a young adulthood cancer. Patients and methods: This retrospective, multicentre study reviewed the medical records of women with SBC before the age of the national screening who had received irradiation (≥3. Gy) on part or all of the breast before 30. years of age, for any type of tumour except BC. Results: A total of 121 SBC were detected in 104 women with previous radiotherapy. Twenty percent of SBC were detected during regular breast screening and 16% of the women had a regular radiological follow-up. Conclusion: Our results points out that the main proportion of childhood cancer survivors did not benefit from the recommended breast cancer screening. This result is comparable to other previously published studies in other countries. A national screening programme is necessary and should take into account the patient's age, family history, personal medical history and previous radiotherapy to reduce the number of SBC diagnosed at an advanced stage. © 2017.


Rousseau C.,ICO Gauducheau | Rousseau C.,French Institute of Health and Medical Research | Lacombe M.,ICO Gauducheau | Pallardy A.,French Institute of Health and Medical Research | And 10 more authors.
Medecine Nucleaire | Year: 2012

Behavioral heterogeneity within a given patient cohort has been a major challenge in clinical practice and is probably most prominently observed in the field of oncology. This has been the prime impetus of the cutting-edge preclinical and clinical research studies over recent times, many of which seek to further stratify patients based on patients' genetic, proteomic, and metabolic profile, in order to select the appropriate therapy according to an individual's best-fit. Molecular imaging of breast cancer can potentially be used for breast cancer staging, restaging, response evaluation and guiding therapies. This review focuses on PET imaging which can provide sensitive serial non-invasive information of tumor characteristics. Increasingly, more breast cancer specific targets are imaged such as estrogen receptor (ER) and growth factors. Although molecular imaging of breast cancer is still not commonly used in daily clinical practice, its application portfolio is expanding rapidly. © 2012 Elsevier Masson SAS.

Loading ICO Gauducheau collaborators
Loading ICO Gauducheau collaborators